Ingrezza (valbenazine) engages with its VMAT2 target more strongly than extended-release Austedo XR (deutetrabenazine), which may translate into…
Articles by Margarida Maia, PhD
In a large Venezuelan family with Huntington’s disease, members with a rare variant in the WDFY3 gene developed symptoms…
The U.S. Food and Drug Administration (FDA) no longer considers available clinical data sufficient to move forward with an application…
Swallowing difficulties start in the early stages of Huntington’s disease (HD) and progress over time, affecting both voluntary movements…
An investigational treatment prepared from stem cells found in young teeth appears to be safe and to help adults with…
Both DNA repair and non-repair genes influence how and when Huntington’s disease develops, according to a study based on…
Introducing small interruptions into the abnormally long CAG repeat expansion that causes Huntington’s disease can stabilize or even reduce…
The U.S. Food and Drug Administration (FDA) has designated uniQure’s gene therapy candidate AMT-130 a breakthrough therapy for its…
Pediatric-onset Huntington’s disease is more severe than its adult-onset form, with faster and more extensive shrinkage of brain regions…
The U.S. Food and Drug Administration (FDA) is supporting financially a study into how well wearable sensors measure two early…